Incyte (INCY) Other Non-Current Liabilities (2013 - 2026)
Incyte (INCY) reported Other Non-Current Liabilities of $126.6 million for Q1 2026, down 27.91% on a YoY basis from $175.6 million in Q1 2025, and down 23.41% quarter-over-quarter from $165.3 million in Q4 2025.
Incyte (INCY) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Incyte has reported Other Non-Current Liabilities for 14 years, with the latest figure at $126.6 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities fell 27.91% year-over-year to $126.6 million; the trailing twelve-month figure through Mar 2026 stood at $126.6 million (down 27.91% YoY), and the FY2025 full-year result was $165.3 million, down 1.36% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $126.6 million, down from $165.3 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $184.5 million in Q4 2022, with the low at $69.5 million in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $148.2 million across 5 years, with a median of $164.8 million in 2024.
- The largest YoY upside for Other Non-Current Liabilities was 175.76% in 2022 against a maximum downside of 65.27% in 2022.
- Incyte's Other Non-Current Liabilities stood at $184.5 million in 2022, then declined by 19.14% to $149.2 million in 2023, then rose by 12.33% to $167.5 million in 2024, then declined by 1.36% to $165.3 million in 2025, then dropped by 23.41% to $126.6 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $126.6 million (Q1 2026), $165.3 million (Q4 2025), and $171.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126.59 Mn |
| Dec 31, 2025 | 165.27 Mn |
| Sep 30, 2025 | 171.18 Mn |
| Jun 30, 2025 | 179.91 Mn |
| Mar 31, 2025 | 175.59 Mn |
| Dec 31, 2024 | 167.54 Mn |
| Sep 30, 2024 | 144.68 Mn |
| Jun 30, 2024 | 142.10 Mn |
| Mar 31, 2024 | 164.84 Mn |
| Dec 31, 2023 | 149.15 Mn |
| Sep 30, 2023 | 133.07 Mn |
| Jun 30, 2023 | 179.49 Mn |
| Mar 31, 2023 | 118.41 Mn |
| Dec 31, 2022 | 184.46 Mn |
| Sep 30, 2022 | 171.81 Mn |
| Jun 30, 2022 | 76.06 Mn |
| Mar 31, 2022 | 69.47 Mn |
| Dec 31, 2021 | 70.41 Mn |
| Sep 30, 2021 | 62.31 Mn |
| Jun 30, 2021 | 219.01 Mn |